摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

乳酸乙基碳酸酯 | 5700-72-1

中文名称
乳酸乙基碳酸酯
中文别名
——
英文名称
2-ethoxycarbonyloxypropionic acid
英文别名
o-Carbethoxylactic acid, DL-;2-ethoxycarbonyloxypropanoic acid
乳酸乙基碳酸酯化学式
CAS
5700-72-1
化学式
C6H10O5
mdl
——
分子量
162.142
InChiKey
JFCWMIUUZIJCCJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 溶解度:
    溶于DCM、乙醚

计算性质

  • 辛醇/水分配系数(LogP):
    0.9
  • 重原子数:
    11
  • 可旋转键数:
    5
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.67
  • 拓扑面积:
    72.8
  • 氢给体数:
    1
  • 氢受体数:
    5

SDS

SDS:7de48bd3d10f7c43c436163fd65904ca
查看

反应信息

  • 作为反应物:
    描述:
    乳酸乙基碳酸酯氯化亚砜 、 sodium carbonate 、 potassium iodide 作用下, 以 氯仿 为溶剂, 反应 50.0h, 生成 1-benzyl-4-(N-(2-ethoxycarbonyloxypropionyl)anilino)piperidine
    参考文献:
    名称:
    Metabolism of fentanyl in isolated hepatocytes from rat and guinea pig.
    摘要:
    通过气相色谱-质谱(GC-MS)结合稳定同位素示踪技术,鉴定了大鼠和豚鼠离体肝细胞中芬太尼(FT)的代谢物。离体肝细胞采用胶原酶灌注法制备,并与 0.3mM 等摩尔 FT 和柠檬酸 FT-d5 混合物在 37°C 旋转圆底烧瓶中培养。代谢物用氯仿提取。提取物经三甲基硅烷化后进行气相色谱和气相色谱-质谱分析。质谱中的特征性双峰表明,在大鼠和豚鼠肝细胞中分别存在 6 种和 7 种代谢物。在这两个物种中,4-(N-丙酰基苯胺基)哌啶被确定为主要代谢物。其他代谢物是 FT 的苯乙基、哌啶基和丙酰基的氧化产物。在肝细胞中未发现苯胺基环的氧化和酰胺键的水解。
    DOI:
    10.1248/cpb.33.3922
  • 作为产物:
    描述:
    在 palladium 10% on activated carbon 、 氢气 作用下, 以 乙醇 为溶剂, 以0.52 g的产率得到乳酸乙基碳酸酯
    参考文献:
    名称:
    [EN] GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEM
    [FR] COMPOSÉS D'ADMINISTRATION DE GAMMA-HYDROXYBUTYRATE ET LEURS PROCÉDÉS DE PRÉPARATION ET MÉTHODES D'UTILISATION
    摘要:
    Disclosed are compounds comprising chemically modified gamma-hydroxybutyrate (GHB) having the structure of Formula I, and salts of such compounds (GHB delivering compounds and salts thereof). Also disclosed are compositions comprising at least one GHB delivering compound, or a salt thereof, methods of making such compounds, and methods of using such GHB delivering compounds and compositions. Methods of treatment are also disclosed.
    公开号:
    WO2023205233A1
点击查看最新优质反应信息

文献信息

  • Use of 2-ethoxy-1-(ethoxycarbonyl)-1, 2-dihydroquinoline as a convenient reagent for the selective protection or derivatization of 2-hydroxycar☐ylic acids
    作者:Myung Ho Hyun、Moon Hee Kang、Sang Cheol Han
    DOI:10.1016/s0040-4039(99)00509-2
    日期:1999.4
    EEDQ has been utilized as a convenient reagent for the selective protection of the hydroxy group of 2-hydroxycar☐ylic acids. In the presence of an appropriate amine nucleophile, EEDQ has also been utilized as a reagent for the derivatization of both of the hydroxy and car☐ylic acid group of 2-hydroxycar☐ylic acids.Figure options
    EEDQ已被用作方便的试剂,用于选择性保护2-羟基羧酸的羟基。在适当的胺亲核试剂的存在下,EEDQ也已被用作用于衍生2-羟基car☐水合酸的羟基和car☐水合酸基团的试剂。图选项
  • 2,3-(dihydro)bicyclic pyrazolidinones
    申请人:ELI LILLY AND COMPANY
    公开号:EP0203723A1
    公开(公告)日:1986-12-03
    2,3-(Dihydro) bicyclic pyrazolidinones are intermediates for bicyclic pyrazolidinone antimicrobials. The intermediates have the formula wherein: either R1 or R2 is hydrogen, C1 to C6 alkyl, C1 to C6 substituted alkyl, perfluoro C2 to C4 alkyl, C7 to C12 alkylaryl, C7 to C12 substituted alkylaryl, phenyl, substituted phenyl or cyano; a group of the formula wherein X is fluoro, chloro, bromo or iodo; a group of the formula wherein z is 0, 1 or 2 and R5 is C, to C6 alkyl, C1 to C6 substituted alkyl, phenyl, substituted phenyl, C7 to C12 alkylaryl, C7 to C12 substituted alkylaryl or a heterocyclic ring; a group of the formula wherein R6 is hydrogen, C1 to C6 alkyl, C1 to C6 substituted alkyl, perfluoro C2 to C4 alkyl, trihalomethyl, C7 to C12 alkylaryl, C7 to C12 substituted alkylaryl, phenyl or substituted phenyl; a group of the formula wherein R7 is hydrogen, an organic or inorganic cation, C1 to C6 alkyl, C1 to C6 substituted alkyl, C7 to C12 alkylaryl, C7 to C12 substituted alkylaryl, phenyl, substituted phenyl, a carboxy protecting group, or a non-toxic, metabolically-labile ester-forming group; or a group of the formula -CH2-S-Heterocyclic ring and the other of Rt or R2 is a group of the formula wherein R8 is hydrogen, an organic or inorganic cation, a carboxy protecting group or a non-toxic, metabolically-labile ester-forming group; R3 and R4 are the same or different and are hydrogen, C1 to C6 alkyl, C1 to C6 substituted alkyl, C7 to C12 alkylaryl, C7 to C12 substituted alkylaryl, phenyl, substituted phenyl or a group of the formula wherein R9 has the same definition as R7; Y is C1 to C6 alkyl, C1 to C6 substituted alkyl, phenyl, substituted phenyl, C7 to C12 alkylaryl or C7 to C12 substituted alkylaryl; or a pharmaceutically acceptable salt thereof.
    2,3-(二氢)双环吡唑烷酮是双环吡唑烷酮抗菌剂的中间体。这些中间体的化学式为 其中 R1 或 R2 为氢、C1 至 C6 烷基、C1 至 C6 取代烷基、全氟 C2 至 C4 烷基、C7 至 C12 烷芳基、C7 至 C12 取代烷芳基、苯基、取代苯基或氰基; 式中的基团 其中 X 为氟、氯、溴或碘; 式中 X 为氟、氯、溴或碘的基团 其中 z 是 0、1 或 2,R5 是 C 至 C6 烷基、C1 至 C6 取代的烷基、苯基、取代的苯基、C7 至 C12 烷芳基、C7 至 C12 取代的烷芳基或杂环; 式中的基团 其中 R6 是氢、C1 至 C6 烷基、C1 至 C6 取代的烷基、全氟 C2 至 C4 烷基、三卤甲基、C7 至 C12 烷芳基、C7 至 C12 取代的烷芳基、苯基或取代的苯基; 式中的基团 其中 R7 是氢、有机或无机阳离子、C1 至 C6 烷基、C1 至 C6 取代的烷基、C7 至 C12 烷芳基、C7 至 C12 取代的烷芳基、苯基、取代的苯基、羧基保护基团或无毒、代谢上易腐烂的成酯基团;或式中的基团 -CH2-S-杂环,而 Rt 或 R2 的另一个是式中的基团 其中 R8 是氢、有机或无机阳离子、羧基保护基团或无毒、代谢上易消化的成酯基团; R3 和 R4 相同或不同,并且是氢、C1 至 C6 烷基、C1 至 C6 取代烷基、C7 至 C12 烷芳基、C7 至 C12 取代烷芳基、苯基、取代苯基或式中的基团 其中 R9 的定义与 R7 相同; Y 是 C1 至 C6 烷基、C1 至 C6 取代的烷基、苯基、取代的苯基、C7 至 C12 烷芳基或 C7 至 C12 取代的烷芳基;或其药学上可接受的盐。
  • 7-Substituted bicyclic pyrazolidinones
    申请人:ELI LILLY AND COMPANY
    公开号:EP0202046A1
    公开(公告)日:1986-11-20
    7-Substituted bicyclic pyrazolidinone compounds as antimicrobials and the corresponding intermediates, are discussed or provided. The use of the antimicrobial compounds in pharmaceutical compositions and in methods for treating bacterial infections is set forth. The pyrazolidinone compounds are of the formula wherein one of R1 and R2 is hydrogen, halo, C1 to C6 alkyl, C1 to C6 substituted alkyl, perfluoro C2 to C4 alkyl, C7 to C12 arylalkyl, C7 to C12 substituted arylalkyl, phenyl, substituted phenyl, a heterocyclic ring, nitro or cyano; a group of the formula wherein X is fluoro, chloro, bromo or iodo; a group of the formula wherein z is 0, 1 or 2 and R7 is C1 to C6 alkyl, C1 to C6 substituted alkyl, phenyl, substituted phenyl, C7 to C12 arylalkyl, C7 to C12 substituted arylalkyl or a heterocyclic ring; a group of the formula wherein R8 is hydrogen, C1 to C6 alkyl, C, to C6 substituted alkyl, perfluoro C2 to C4 alkyl, trihalomethyl, C7 to C12 arylalkyl, C7 to C12 substituted arylalkyl, phenyl, substituted phenyl, amino, (monosubstituted)amino, or (disubstituted)amino; a group of the formula wherein R9 is hydrogen, an organic or inorganic cation, C1 to C6 alkyl, C1 to C6 substituted alkyl, C7 to C12 arylalkyl, C7 to C12 substituted arylalkyl, phenyl, substituted phenyl, a carboxy-protecting group, or a non-toxic, metabolically-labile, ester-forming group; a group of the formula wherein R10 is hydrogen, an organic or inorganic cation, C1 to C5 alkyl, C, to G6 aubatituted allcyl, C7 to C12 arylalkyl, C7 to C12 aubatltuted arylalkyl, phenyl, or substituted phenyl; a group of the formula ⊕ wherein -N≡Q is a quaternary ammonium group; or a group of the formula -CH2-S-Heterocycllc ring; a group of the formula wherein R11 is hydrogen, C1 to Ce alkyl, C, to Ce substituted alkyl, C7 to C12 arylalkyl, C7 to C12 substituted arylalkyl, phenyl, substituted phenyl or C1 to C7 acyl; or a group of the formula wherein R12 and R13 are the same or different and are hydrogen, C1 to C6 alkyl, C1 to C6 substituted alkyl, C7 to C12 arylalkyl, C7 to C12 substituted arylalkyl, phenyl, substituted phenyl, C1 to C7 acyl, or a group of the formula; wherein Rq is C, to C6 alkyl, C7 to C12 arylalkyl or phenyl; and the other of R, and R2 is a group of the formula wherein R14 is hydrogen, an organic or inorganic cation, a carboxy-protecting group or a non-toxic, metabolically-labile ester-forming group; and R3 and R4 are the same or different and are hydrogen, C1 to C6 alkyl, C1 to C6 substituted alkyl, C7 to C12 arylalkyl, C7 to C12 substituted arylalkyl, phenyl, substituted phenyl or a group of the formula wherein R15 has the same definition as R9; R5 and R6 are: 1) each hydrogen, an amino protecting group; or acyl group derived from a C, to C30 carboxylic acid; provided that at least one of Rs and R6 must be hydrogen; or 2) taken together to form a phthalimido group; or a pharmaceutically-acceptable salt thereof.
    讨论或提供了作为抗菌剂的 7-取代双环吡唑烷酮化合物及相应的中间体。阐述了抗菌化合物在药物组合物和治疗细菌感染方法中的用途。吡唑烷酮化合物的结构式如下 其中 R1 和 R2 之一为氢、卤素、C1 至 C6 烷基、C1 至 C6 取代烷基、全氟 C2 至 C4 烷基、C7 至 C12 芳烷基、C7 至 C12 取代芳烷基、苯基、取代苯基、杂环、硝基或氰基; 式中的基团 其中 X 是氟、氯、溴或碘; 式中的基团 其中 z 是 0、1 或 2,R7 是 C1 至 C6 烷基、C1 至 C6 取代的烷基、苯基、取代的苯基、C7 至 C12 芳烷基、C7 至 C12 取代的芳烷基或杂环; 式中的基团 其中 R8 是氢、C1 至 C6 烷基、C, 至 C6 取代的烷基、全氟 C2 至 C4 烷基、三卤甲基、C7 至 C12 芳烷基、C7 至 C12 取代的芳烷基、苯基、取代的苯基、氨基、(单取代)氨基或(二取代)氨基; 式中的基团 其中 R9 是氢、有机或无机阳离子、C1~C6 烷基、C1~C6 取代的烷基、C7~C12 芳烷基、C7~C12 取代的芳烷基、苯基、取代的苯基、羧基保护基团或无毒、代谢上易腐烂的酯形成基团; 式中的基团 其中 R10 是氢、有机或无机阳离子、C1 至 C5 烷基、C, 至 G6 亚氨基全烷基、C7 至 C12 芳烷基、C7 至 C12 亚氨基芳烷基、苯基或取代苯基; 式中的基团 ⊕ 其中-N≡Q 是季铵基团;或式中-CH2-S-杂环的基团; 式中的基团 其中 R11 是氢、C1 至 Ce 烷基、C1 至 Ce 取代的烷基、C7 至 C12 芳烷基、C7 至 C12 取代的芳烷基、苯基、取代的苯基或 C1 至 C7酰基;或式中的基团 其中 R12 和 R13 相同或不同,并且是氢、C1 至 C6 烷基、C1 至 C6 取代的烷基、C7 至 C12 芳烷基、C7 至 C12 取代的芳烷基、苯基、取代的苯基、C1 至 C7酰基或式中的基团; 其中 Rq 是 C 至 C6 烷基、C7 至 C12 芳烷基或苯基;以及 R 和 R2 中的另一个是式中的基团 其中 R14 是氢、有机或无机阳离子、羧基保护基团或无毒、可代谢的成酯基团; R3 和 R4 相同或不同,并且是氢、C1 至 C6 烷基、C1 至 C6 取代的烷基、C7 至 C12 芳烷基、C7 至 C12 取代的芳烷基、苯基、取代的苯基或式中的一个基团。 其中 R15 的定义与 R9 相同; R5 和 R6 为 1) 各为氢、氨基保护基;或由 C 至 C30 羧酸衍生的酰基; 但 Rs 和 R6 中至少有一个必须是氢;或 2) 结合在一起形成邻苯二甲酰亚胺基团;或其药学上可接受的盐。
  • Bicyclic pyrazolidinones
    申请人:ELI LILLY AND COMPANY
    公开号:EP0203722A1
    公开(公告)日:1986-12-03
    Bicyclic pyrazolidinones which have antimicrobial and/or herbicidal properties are discussed. The use of these compounds in pharmaceutical compositions, herbicidal compositions, and methods for treating bacterial infections and controlling undesired plants is set forth. The bicyclic pyrazolidinones have the formula wherein: either R1 or R2 is hydrogen, C1 to C6 alkyl, C1 to C6 substituted alkyl, perfluoro C2 to C4 alkyl, C7 to C12 alkylaryl, C7 to C12 substituted alkylaryl, phenyl, substituted phenyl, nitro br cyano; a group of the formula wherein X is fluoro, chloro, bromo or iodo; a group of the formula wherein Z is 0, 1 or 2 and Rs is C1 to C6 alkyl, C1 to C6 substituted alkyl, phenyl, substituted phenyl, C7 to C12 alkylaryl, C7 to C12 substituted alkylaryl or a heterocyclic ring; a group of the formula wherein R6 is hydrogen, C1 to C6 alkyl, C1 to C6 substituted alkyl, perfluoro C2 to C4 alkyl, trihalomethyl, C7 to C12 alkylaryl, C7 to C12 substituted alkylaryl, phenyl or substituted phenyl; a group of the formula wherein R7 is hydrogen, an organic or inorganic cation, C1 to C6 alkyl, C1 to C6 substituted alkyl, C7 to C12 alkylaryl, C7 to C12 substituted alkylaryl, phenyl, substituted phenyl, a carboxy protecting group, or a non-toxic, metabolically-labile ester-forming group; or a group of the formula wherein R8 is hydrogen, C1 to C6 alkyl, C1 to C6 substituted alkyl, C7 to C12 substituted alkylaryl, phenyl, or substituted phenyl; a group of the formula wherein -N≡Q is a quaternary ammonium group; or a group of the formula -CH2-S-Heterocyclic-ring and the other of R1 or R2 is a group of the formula wherein R9 is hydrogen, an organic or inorganic cation, a carboxy protecting group, or a non-toxic, metabolically-labile ester-forming group; and R3 and R4 are the same or different and are hydrogen, C1 to C6 alkyl, C1 to C6 substituted alkyl, C7 to C12 alkylaryl, C7 to C12 substituted alkylaryl, phenyl, substituted phenyl or a group of the formula wherein R10 has the same definition as R7; with the exception that, when R1 and R2 are a group of the formula R3 and R4 are not methyl; or a pharmaceutically-acceptable salt thereof.
    本文讨论了具有抗菌和/或除草特性的双环吡唑烷酮。阐述了这些化合物在药物组合物、除草组合物中的用途,以及治疗细菌感染和控制有害植物的方法。双环吡唑烷酮的化学式为 其中 R1 或 R2 是氢、C1 至 C6 烷基、C1 至 C6 取代烷基、全氟 C2 至 C4 烷基、C7 至 C12 烷芳基、C7 至 C12 取代烷芳基、苯基、取代苯基、硝基溴氰基; 式中的基团 其中 X 为氟、氯、溴或碘; 式中的基团 其中 Z 是 0、1 或 2,Rs 是 C1 至 C6 烷基、C1 至 C6 取代的烷基、苯基、取代的苯基、C7 至 C12 烷芳基、C7 至 C12 取代的烷芳基或杂环; 式中的基团 其中 R6 是氢、C1 至 C6 烷基、C1 至 C6 取代的烷基、全氟 C2 至 C4 烷基、三卤甲基、C7 至 C12 烷芳基、C7 至 C12 取代的烷芳基、苯基或取代的苯基; 式中的基团 其中 R7 是氢、有机或无机阳离子、C1-C6 烷基、C1-C6 取代烷基、C7-C12 烷芳基、C7-C12 取代烷芳基、苯基、取代苯基、羧基保护基团或无毒、代谢上易形成酯的基团; 或一个式中的基团 其中 R8 是氢、C1 至 C6 烷基、C1 至 C6 取代的烷基、C7 至 C12 取代的烷芳基、苯基或取代的苯基; 式中的基团 其中 -N≡Q 是季铵基团; 或式中的基团 -CH2-S-杂环,而 R1 或 R2 中的另一个是式中的基团 其中 R9 是氢、有机或无机阳离子、羧基保护基团或无毒、可代谢的成酯基团;以及 R3 和 R4 相同或不同,并且是氢、C1 至 C6 烷基、C1 至 C6 取代的烷基、C7 至 C12 烷芳基、C7 至 C12 取代的烷芳基、苯基、取代的苯基或式中的基团 其中 R10 的定义与 R7 相同;但当 R1 和 R2 为式中的基团时 R3 和 R4 不是甲基;或其药学上可接受的盐。
  • US4716232A
    申请人:——
    公开号:US4716232A
    公开(公告)日:1987-12-29
查看更多